Non-Current Liabilities
Operating Lease Liabilities
Neurocrine Biosciences Operating Lease Liabilities decreased by 2.2% to $406.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.2%, from $447.50M to $406.20M. Over 5 years (FY 2020 to FY 2025), Operating Lease Liabilities shows an upward trend with a 34.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ4 2018
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase reflects long-term expansion of the leased asset base, while a decrease indicates a reduction in long-term lease commitments.
Detailed definition
This represents the portion of operating lease obligations that are due beyond the next twelve months. It reflects the l...
Peer comparison
Standard long-term liability for companies with significant real estate or equipment footprints.
Metric ID:
operating_lease_liabilities_non_currentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $109.00M | $106.40M | $105.30M | $102.50M | $99.60M | $96.60M | $93.50M | $90.40M | $89.10M | $85.90M | $258.30M | $252.90M | $256.20M | $251.40M | $455.10M | $447.50M | $439.10M | $428.40M | $415.30M | $406.20M |
| QoQ Change | — | -2.4% | -1.0% | -2.7% | -2.8% | -3.0% | -3.2% | -3.3% | -1.4% | -3.6% | +200.7% | -2.1% | +1.3% | -1.9% | +81.0% | -1.7% | -1.9% | -2.4% | -3.1% | -2.2% |
| YoY Change | — | — | — | — | -8.6% | -9.2% | -11.2% | -11.8% | -10.5% | -11.1% | +176.3% | +179.8% | +187.5% | +192.7% | +76.2% | +76.9% | +71.4% | +70.4% | -8.7% | -9.2% |
Range$85.90M – $455.10M
CAGR+31.9%
Avg YoY Growth+59.4%
Median YoY Growth+30.9%
Current Streak5 quarters decline
Operating Lease Liabilities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating lease liabilities?
- Neurocrine Biosciences (NBIX) reported operating lease liabilities of $406.20M in Q1 2026.
- How has Neurocrine Biosciences's operating lease liabilities changed year-over-year?
- Neurocrine Biosciences's operating lease liabilities decreased by 9.2% year-over-year, from $447.50M to $406.20M.
- What is the long-term trend for Neurocrine Biosciences's operating lease liabilities?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's operating lease liabilities has grown at a 34.5% compound annual growth rate (CAGR), from $94.40M to $415.30M.
- What does operating lease liabilities mean?
- The amount of lease payments due after one year.